Charles Schwab’s Aldeyra Therapeutics ALDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-139,029
| Closed | -$235K | – | 3445 |
|
|
2026
Q1 | $235K | Sell |
139,029
-13,758
| -9% | -$60.3K | ﹤0.01% | 3287 |
|
|
2025
Q4 | $791K | Buy |
152,787
+2,309
| +2% | +$11.9K | ﹤0.01% | 3002 |
|
|
2025
Q3 | $785K | Sell |
150,478
-7,060
| -4% | -$36.8K | ﹤0.01% | 3031 |
|
|
2025
Q2 | $603K | Buy |
157,538
+19,553
| +14% | +$50.5K | ﹤0.01% | 3076 |
|
|
2025
Q1 | $793K | Buy |
137,985
+1,252
| +0.9% | +$7.4K | ﹤0.01% | 2920 |
|
|
2024
Q4 | $682K | Hold |
136,733
| – | – | ﹤0.01% | 3047 |
|
|
2024
Q3 | $737K | Hold |
136,733
| – | – | ﹤0.01% | 3018 |
|
|
2024
Q2 | $453K | Buy |
136,733
+11,208
| +9% | +$43.9K | ﹤0.01% | 3240 |
|
|
2024
Q1 | $410K | Hold |
125,525
| – | – | ﹤0.01% | 3099 |
|
|
2023
Q4 | $441K | Hold |
125,525
| – | – | ﹤0.01% | 3123 |
|
|
2023
Q3 | $839K | Hold |
125,525
| – | – | ﹤0.01% | 2860 |
|
|
2023
Q2 | $1.05M | Buy |
125,525
+103,324
| +465% | +$1.02M | ﹤0.01% | 2756 |
|
|
2023
Q1 | $220K | Hold |
22,201
| – | – | ﹤0.01% | 3137 |
|
|
2022
Q4 | $155K | Hold |
22,201
| – | – | ﹤0.01% | 3221 |
|
|
2022
Q3 | $119K | Hold |
22,201
| – | – | ﹤0.01% | 3211 |
|
|
2022
Q2 | $89K | Sell |
22,201
-110,707
| -83% | -$381K | ﹤0.01% | 3299 |
|
|
2022
Q1 | $591K | Buy |
132,908
+4,523
| +4% | +$18K | ﹤0.01% | 3051 |
|
|
2021
Q4 | $514K | Buy |
128,385
+3,699
| +3% | +$28.2K | ﹤0.01% | 3136 |
|
|
2021
Q3 | $1.09M | Sell |
124,686
-413
| -0.3% | -$3.79K | ﹤0.01% | 2842 |
|
|
2021
Q2 | $1.42M | Buy |
125,099
+106,972
| +590% | +$1.29M | ﹤0.01% | 2820 |
|
|
2021
Q1 | $216K | Hold |
18,127
| – | – | ﹤0.01% | 3305 |
|
|
2020
Q4 | $125K | Hold |
18,127
| – | – | ﹤0.01% | 3302 |
|
|
2020
Q3 | $135K | Buy |
+18,127
| New | +$117K | ﹤0.01% | 3229 |
|
|
2020
Q2 | – | Sell |
-52,683
| Closed | -$131K | – | 3321 |
|
|
2020
Q1 | $131K | Sell |
52,683
-4,964
| -9% | -$22.3K | ﹤0.01% | 3080 |
|
|
2019
Q4 | $335K | Buy |
57,647
+4,111
| +8% | +$23.7K | ﹤0.01% | 2952 |
|
|
2019
Q3 | $283K | Sell |
53,536
-8,000
| -13% | -$43.1K | ﹤0.01% | 2980 |
|
|
2019
Q2 | $370K | Buy |
61,536
+19,826
| +48% | +$149K | ﹤0.01% | 2951 |
|
|
2019
Q1 | $377K | Sell |
41,710
-5,100
| -11% | -$43.3K | ﹤0.01% | 2864 |
|
|
2018
Q4 | $389K | Buy |
46,810
+17,110
| +58% | +$175K | ﹤0.01% | 2848 |
|
|
2018
Q3 | $410K | Hold |
29,700
| – | – | ﹤0.01% | 2908 |
|
|
2018
Q2 | $237K | Buy |
+29,700
| New | +$237K | ﹤0.01% | 3040 |
|
Other funds holding ALDX
KCM
KCM
6CM
Charles Schwab's ALDX Position: Q2 2026 in Review
Charles Schwab sold out of Aldeyra Therapeutics (ALDX) in Q2 2026, closing a stake of 139,029 shares — an estimated $235K sold.
Charles Schwab first reported a position in ALDX in Q2 2018 and held it in 31 quarters. The position peaked at $1.42M in Q2 2021. 108 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.
- Charles Schwab reported no remaining Aldeyra Therapeutics position as of Q2 2026 after selling out during the quarter.
- Charles Schwab sold 139,029 Aldeyra Therapeutics shares in Q2 2026, an estimated $235K.
- Charles Schwab first reported a position in Aldeyra Therapeutics in Q2 2018 and held it in 31 quarters.
- Charles Schwab's Aldeyra Therapeutics position peaked at $1.42M in Q2 2021.
- 108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.